New shot tested to stop deadly fever outbreak
NCT ID NCT06799234
Summary
This study is testing a new vaccine, called ChAdOx1 RVF, to protect adults in Kenya from Rift Valley Fever, a serious mosquito-borne disease. Researchers will give the vaccine to 240 healthy adults to see if it safely triggers a strong and lasting immune response. They will compare people who get one dose, two doses, or a different rabies vaccine, and monitor everyone for 18 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFT VALLEY FEVER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
KEMRI-Wellcome Trust Research Programme
Kilifi, Coast, 254, Kenya
Conditions
Explore the condition pages connected to this study.